Showing results (11-20 of 26) with videos related to

Sort By:
Pageof 3
British Journal of Haematology|January 26, 2023
The Rory Morrison WMUK Registry for Waldenström macroglobulinaemia: The growth of a national registry for a rare disorderEncarl Uppal, Jahanzaib Khwaja, Joshua Bomsztyk, et al.
Ejhaem|February 23, 2023
Patient reported outcome measures in Waldenström macroglobulinaemia: A real-world data analysis from the WMUK Rory Morrison RegistryJahanzaib Khwaja, Encarl Uppal, Sotirios Bristogiannis, et al.
British Journal of Haematology|May 30, 2019
Long term outcomes in monoclonal gammopathy of renal significanceAkhil Khera, Fotios Panitsas, Faouzi Djebbari, et al.
British Journal of Haematology|January 21, 2014
Autologous stem cell transplantation for follicular lymphoma is of most benefit early in the disease course and can result in durable remissions, irrespective of prior rituximab exposureJaimal Kothari, Karl S Peggs, Antonia Bird, et al.
Plos One|July 7, 2022
Panobinostat in combination with bortezomib and dexamethasone in multiply relapsed and refractory myeloma; UK routine care cohortNadjoua Maouche, Bhuvan Kishore, Zara Bhatti, et al.
Leukemia & Lymphoma|December 28, 2020
Ixazomib, lenalidomide, and dexamethasone is effective and well tolerated in multiply relapsed (≥2nd relapse) refractory myeloma: a multicenter real world UK experienceNadjoua Maouche, Bhuvan Kishore, Matthew W Jenner, et al.
British Journal of Haematology|March 10, 2016
Results of a multicentre UK-wide retrospective study evaluating the efficacy of pixantrone in relapsed, refractory diffuse large B cell lymphomaToby A Eyre, Kim M Linton, Phillipa Rohman, et al.
British Journal of Haematology|August 20, 2024
PembroWM: A phase II trial to investigate the safety and efficacy of rituximab and pembrolizumab in relapsed/refractory Waldenström's MacroglobulinaemiaJaimal Kothari, Toby Eyre, Ali Rismani, et al.
European Journal of Haematology|January 26, 2021
Efficacy and tolerability of VCD chemotherapy in a UK real-world dataset of elderly transplant-ineligible newly diagnosed myeloma patientsAlexandros Rampotas, Faouzi Djebbari, Fotios Panitsas, et al.
Plos One|January 11, 2022
Evaluation of the frailty characteristics and clinical outcomes according to the new frailty-based outcome prediction model (Myeloma Risk Profile-MRP) in a UK real-world cohort of elderly newly diagnosed Myeloma patientsFaouzi Djebbari, Alexandros Rampotas, Fotios Panitsas, et al.
Pageof 3